Pfizer Logo

Pfizer COVID-19 Vaccine Production and Distribution Working Well

Thursday, December 17, 2020 - 11:51am

New York, NY, December 17, 2020 – Pfizer Inc. (NYSE: PFE) today released the following statement to address public comments that allege there are issues in the production and distribution of the company's COVID-19 vaccine:

"Pfizer is not having any production issues with our COVID-19 vaccine, and no shipments containing the vaccine are on hold or delayed. This week, we successfully shipped all 2.9 million doses that we were asked to ship by the U.S. Government to the locations specified by them. We have millions more doses sitting in our warehouse but, as of now, we have not received any shipment instructions for additional doses.

We have continuously shared with Operation Warp Speed (OWS) and the U.S. Department of Health and Human Services through weekly meetings every aspect of our production and distribution capabilities. They have visited our facilities, walked the production lines and been updated on our production planning as information has become available.

Pfizer has a successful and long track record of producing and distributing large volumes of complex vaccines that the world can trust – and we are continuing to extend this track record with our COVID-19 vaccine. Over the last several months, we have activated Pfizer's extensive manufacturing network, including thousands of highly skilled workers in multiple locations. As a result, Pfizer is manufacturing and readying for release millions of doses each day, and that volume will grow over the coming weeks.

We remain confident in our ability to deliver up to 50 million doses globally this year and up to 1.3 billion next year, and we look forward to continuing to work with the US Government to deliver our vaccine to the American people."

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com.